Open an account

Cocrystal Pharma

COCP · NASDAQ

$0.9429−$0.0037 (−0.39%)TodayMarket closed ·
Prev close $0.9466

About COCP

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. The company is headquartered in Bothell, Washington and currently employs 10 full-time employees. The company went IPO on 2018-03-12. The firm is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). The company is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. The company has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. The company also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Employees
10
Headquarters
Bothell, Washington
Listed
Mar 12, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
cocrystalpharma.com

COCP key statistics

Market cap
18.16M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
45.51K
Volume
15.35K
Open price
$0.9145
High today
$0.976
Low today
$0.9101
52 Week high
$2.03
52 Week low
$0.76

Cocrystal Pharma (COCP) at a glance

Cocrystal Pharma (COCP) last traded at $0.9429, with a market cap of 18.16M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.9101 and $0.976. The current price is 3.6% above the day's low and 3.4% below its high.

Volume so far is 15.35K shares, below the average of 45.51K shares a day.

Over the past year Cocrystal Pharma has ranged from $0.76 to $2.03, and now sits 14% of the way up that range.

Cocrystal Pharma met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.23 per share against an estimate of -$0.1683.

COCP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 27.1% on average.

  1. Q3 FY24: reported -$0.49 per share against an estimate of -$0.5814
  2. Q4 FY24: reported -$0.32 per share against an estimate of -$0.5406
  3. Q1 FY25: reported -$0.23 per share against an estimate of -$0.5151
  4. Q2 FY25: reported -$0.20 per share against an estimate of -$0.306
  5. Q3 FY25: reported -$0.19 per share against an estimate of -$0.2142
  6. Q4 FY25: reported -$0.17 per share against an estimate of -$0.1785
  7. Q1 FY26: reported -$0.17 per share against an estimate of -$0.153
  8. Q2 FY26: reported -$0.23 per share against an estimate of -$0.1683

COCP news

  • Watching Cocrystal Pharma; Zacks-Small Cap Research Gives Stock $8 Price Valuation

  • Kaustubh Bagalkote

    Why Cocrystal Pharma Shares Are Cooling Off Monday?

  • Avi Kapoor

    Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Nasdaq Down 1%; US Initial Jobless Claims Fall

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Similar companies

Companies in the same industry as Cocrystal Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.